Proneuron’s ProCord Therapy for the Treatment of Acute Spinal Cord Injury featured in News Report on International Herald Tribune Television (IHT-TV)
broadcast in 90 Countries Worldwide starting January 9-15, 2004

---

The International Herald Tribune television (IHT-TV) news package on Proneuron’s ProCord Therapy is part of the programming for a show called  IHT World or World Business, depending on the channel.

A video stream of the package is now available on the SpineUniverse website (www.spineuniverse.com), via the following links:

• View on Modem Connection
• View on High Speed Connection

---

Patient, Immediate Family of Patient and/or Physician inquiries:
24 hour a day Patient Recruitment Center:
Email: clinical.trial@proneuron.com ; Telephone: 1 866 539 0767 (U.S. toll free) or 1 506 652 3486; Fax: 1 866-214-7078 *Callers outside of the U.S., please use standard international dialing code.

About Proneuron Biotechnologies
Proneuron Biotechnologies, Inc. is a privately held biopharmaceutical company developing products for the medical treatment of spinal cord injuries and other disorders of the central nervous system. Its products are based on proprietary technology for modulating the interaction between the nervous and the immune systems. The company is currently engaged in several clinical studies located in the U.S., Belgium and Israel. These include: a trial of Macrophage therapy for the treatment of spinal cord injuries and a trial of Cop-1 for the treatment of Huntington’s disease (HD). In 2001, Proneuron entered into a strategic collaboration with Teva to develop and commercialize Cop-1 for various indications other than HD and ALS, which are being independently developed by Proneuron. The Company is also developing PN277 for the treatment of additional neurodegenerative diseases.

Press inquiries: Marjie Hadad, Marjie.hadad@proneuron.com, Marjie@netvision.net.ilil; +972-55-365-220